Oncology News

Cirrhotic patients with hepatocellular carcinoma have significantly poorer survival when they experience therapeutic delays, according to data presented at the International Liver Cancer Association Annual Conference in Washington, DC.

A longer duration of progression-free survival on sorafenib therapy for hepatocellular carcinoma was associated with more adverse events, lower alpha-fetoprotein levels and fewer tumors with extrahepatic spread in a study presented at the International Liver Cancer Association Annual Conference in Washington, DC.

Brivanib did not improve survival among patients with hepatocellular carcinoma who underwent transcatheter arterial chemoembolization in a study presented at the International Liver Cancer Association Annual Conference in Washington, DC.

Performing ultrasound once every 6 months is the most cost-effective way to screen for hepatocellular carcinoma in patients with cirrhosis, according to data presented at the International Liver Cancer Association Annual Conference in Washington, DC.

Patients with dysplastic nodules due to chronic hepatitis B infection were more likely to progress to hepatocellular carcinoma with higher HBV viral loads in a study presented at the International Liver Cancer Association Annual Conference in Washington, DC.

Patients with hepatocellular carcinoma who experienced dermatologic side effects while treated with sorafenib had improved survival in a study presented at the International Liver Cancer Association Annual Conference in Washington, DC.

Patients with hepatocellular carcinoma who experienced dermatologic side effects while treated with sorafenib had improved survival in a study presented at the International Liver Cancer Association Annual Conference in Washington, DC.

Patients with hepatocellular carcinoma of smaller size experienced similar survival and safety outcomes from hepatic resection and radiofrequency ablation in a study presented at the International Liver Cancer Association Annual Conference in Washington, DC.

The number of patients in the US with hepatocellular carcinoma who undergo both any or specifically curative treatment is low, including those diagnosed at an early stage, according to recent results.

The number of patients in the US with hepatocellular carcinoma who undergo both any or specifically curative treatment is low, including those diagnosed at an early stage, according to recent results.